AbbVie Inc. Stock Rises Tuesday, Still Underperforms Market

Amesite Inc

Change company Symbol lookup

Select an option...

AMST Amesite Inc

AMPX Amprius Technologies Inc

PRTK Paratek Pharmaceuticals Inc

EGRAY Energy Resources Of Australia Ltd

IVAC Intevac Inc

PFE Pfizer Inc

BNOX Bionomics Ltd

CRKN Crown Electrokinetics Corp.

CAE CAE Inc

YMAB Y-mAbs Therapeutics Inc

Consumer Discretionary : Diversified Consumer Services | Small Cap Value

Company profile

Amesite, Inc. is an artificial intelligence software company. The Company is engaged in offering a cloud-based platform and content creation services for business and university-delivered education and upskilling. It uses artificial intelligence technologies to provide customized environments for learners, easy-to-manage interfaces for instructors, and accessibility for learners in the United States education market. Its code architecture offers accessibility and agility for engineers, using languages for both client and server-side functions. It delivers Learning Community Environments (LCESMs) to businesses and educational institutions (EIs) that enable them to offer branded learning products to their students, professional learners or employees with ease. It offers its platform to its customers, which include universities, museums, businesses and government agencies. Its customers offer learning to their users, who are students, professional learners and / or their own employees.

AbbVie Inc. Stock Rises Tuesday, Still Underperforms Market

4:33 pm ET January 31, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) rallied 1.44% to $147.75 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 1.46% to 4,076.60 and the Dow Jones Industrial Average rising 1.09% to 34,086.04. The stock's rise snapped a three-day losing streak. AbbVie Inc. closed $28.16 below its 52-week high ($175.91), which the company reached on April 8th.

The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.88% to $163.42 and Pfizer Inc. (PFE) rose 1.40% to $44.16. Trading volume (5.6 M) eclipsed its 50-day average volume of 5.4 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 31, 2023.

(END) Dow Jones Newswires

January 31, 2023 16:33 ET (21:33 GMT)